anoth guidanc cut cast lt outlook
report anoth soft quarter revenu cc
jpme/consensu jpme cc although ep
came jpme/street aid buy-back
weak attribut industri cc offset strength pharma
cc driven resumpt capit budget releas larg custom
well improv china winner round
tender resum purchas look ahead reduc
guidanc top bottom line attribut disappoint ytd
perform deterior industri outlook call full-year
revenu growth cc cc ep rang
despit signific buy-back step back
pharma improv encourag updat guidanc
assum continu pharma improv industri soft
echo yesterday result guidanc cut alreadi low
base believ certainli paint dimmer outlook previous expect
addit consid china gener pharma given upcom round
tender eventu nation roll-out note preview food
test remain headwind near futur new product
bioaccord newli launch high-resolut mass spec take multipl
quarter ramp continu reserv around abil
achiev long-term growth outlook given uncertain growth
trajectori greater cyclic risk vs peer limit room margin
expans continu view current valuat ebitda price-to-earnings
full remain underweight establish dec pt
top-lin growth remain tepid bottom-lin continu
support buy-back report revenu cc
jpme/consensu jpme cc although
ep came jpme/street aid
buy-back end market weak attribut industri cc
particular soft europ offset pharma strength cc
driven resumpt capit budget releas larg custom well
improv china winner round tender
resum purchas govt/academ flat cc comp
remain stabl biomed research strength europ korea
off-set soft china concentr food safeti region
america improv cc vs flat last quarter asia
remain soft vs cc last quarter china
improv pharma stabil food offset weak
academic/govern india also stabil europ continu
declin cc industri declin off-set solid pharma perform
bottom line ep came jpme/street
aid buy-back
sourc style exposur morgan quantit deriv strategi tabl compani data morgan estim
page analyst certif import disclosur
 morgan seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report singl
factor make invest decis
summari invest thesi valuat
given near-peak margin structur unlik
improv meaning current level view
increas competit dynam believ name
within coverag univers present appeal risk-
reward could look becom construct
pullback compani still gener signific cash flow
highest oper margin within industri
continu endors high-roic invest
price target deriv dcf analysi
use termin growth wacc
million
cash-flow oper
margin growth
sourc perform driver bloomberg morgan quantit deriv strategi tabl compani data morgan estim
guidanc reduc weak ytd perform worsen
industri outlook look ahead reduc guidanc
top bottom-lin call full-year revenu growth
cc cc ep rang despit
signific buy-back reduct primarili attribut disappoint ytd
perform deterior industri outlook particularli europ
lsd growth expect ta manag expect solid perform
pharma larg custom capital-expenditure activ normal continu balanc
develop china gener pharma food headwind linger
signific improv deterior although note preview
expect upcom round tender eventu nation roll-out remain
overhang least next year recoveri solid growth india
expect cc growth ep vs street
maintain underweight overal pharma improv
encourag updat guidanc assum continu pharma
improv industri soft echo yesterday
result guidanc cut alreadi low base paint dimmer outlook
previous expect addit consid china gener pharma given
upcom round tender eventu nation roll-out note
preview food test remain headwind near futur new
product bioaccord newli launch high-resolut mass spec take
multipl quarter ramp continu reserv around abil
achiev long-term growth outlook given uncertain growth
trajectori greater cyclic risk vs peer limit room margin expans
continu view current valuat ebitda price-to-earnings full
remain underweight establish dec pt previous
dec price target
compani report bloomberg morgan estim
invest thesi valuat risk
given near-peak margin structur unlik improv meaning
current level view increas competit dynam believ
name within coverag univers present appeal risk-reward could
look becom construct pullback compani still gener
signific cash flow highest oper margin within industri
continu endors high-roic invest
price target deriv dcf analysi use termin growth
wacc
risk rate price
upsid risk price target underweight rate includ greater-than-
anticip traction newer product well outsiz growth
lc ms servic
good sold
chang gross margin y/i bp
chang op margin y/i bp
pv termin valu
perpetu growth rate
enterpris valu
water summari financi
cash equival
flow oper activ
o/w chang work capit
flow invest activ
sale
flow financ activ
net chang cash
adj free cash flow firm
compani report morgan estim
note million except per-shar data fiscal year end dec o/w
analyst certif author name within report research analyst unless otherwis specifi research analyst
denot ac cover report certifi multipl research analyst primarili respons report
research analyst denot ac cover within document individu certifi respect secur issuer
research analyst cover research view express report accur reflect person view
subject secur issuer part research analyst compens
directli indirectli relat specif recommend view express research analyst report korea-
base research analyst list front cover applic also certifi per kofia requir analysi made
good faith view reflect opinion without undu influenc intervent
